Anti-Proliferative and Anti-Tumor Effect of α-Interferon in Renal Cell Carcinoma: Correlation with the Expression of a Kidney Associated Differentiation Glycoprotein
Approximately 20000 cases of renal cell carcinoma (RCC) are diagnosed annually in the US. About 25% of these patients have overt metastatic disease at the time of presentation. The median duration of survival in these patients have been reported to be approximately 10 months. Among the rest of the patients with cancers apparently localized to the kidney, the sole effective therapy is surgical excision of the cancer, typically by a radical nephrectomy. About one third of these patients with apparently localized disease (i.e., 25% of the total) will later manifest metastatic disease and ultimately succumb to the cancer. The annual mortality rate for renal cancer in the US is approximately 10 000.
KeywordsRenal Cell Carcinoma Renal Cancer Advanced Renal Cell Carcinoma Renal Cell Carcinoma Cell Line Gp160 Expression
Unable to display preview. Download preview PDF.